ENTRY       D09314                      Drug
NAME        Ofatumumab (USAN/INN);
            Ofatumumab (genetical recombination) (JAN);
            Arzerra (TN);
            Kesimpta (TN)
PRODUCT     ARZERRA (Novartis Pharmaceuticals Corporation)
            KESIMPTA (Novartis Pharmaceuticals Corporation)
FORMULA     C6480H10022N1742O2020S44
EXACT_MASS  145970.276
MOL_WEIGHT  146060.2301
REMARK      Therapeutic category: 1190
            ATC code: L01FA02 L04AA52
            Product: D09314<JP/US>
EFFICACY    Antineoplastic, Anti-CD20 antibody
  DISEASE   Chronic lymphocytic leukemia [DS:H00005]
            Multiple sclerosis [DS:H01490]
  TYPE      Monoclonal antibody
TARGET      CD20 [HSA:931] [KO:K06466]
  PATHWAY   hsa04640(931)  Hematopoietic cell lineage
INTERACTION  
STR_MAP     map07050  Antirheumatics - DMARDs and biological agents
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
                L01FA CD20 (Clusters of Differentiation 20) inhibitors
                 L01FA02 Ofatumumab
                  D09314  Ofatumumab (USAN/INN) &lt;JP/US&gt;
              L04 IMMUNOSUPPRESSANTS
               L04A IMMUNOSUPPRESSANTS
                L04AA Selective immunosuppressants
                 L04AA52 Ofatumumab
                  D09314  Ofatumumab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Ofatumumab
                D09314  Ofatumumab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             1  Agents affecting nervous system and sensory organs
              11  Agents affecting central nervous system
               119  Miscellaneous
                1190  Miscellaneous
                 D09314  Ofatumumab (USAN/INN); Ofatumumab (genetical recombination) (JAN)
            Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Other cell surface molecules
               CD molecules
                CD20
                 D09314  Ofatumumab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D09314
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D09314
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D09314
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D09314
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D09314
DBLINKS     CAS: 679818-59-8
            PubChem: 96025994
///
